Shireen Alwani, NP
Nurse Practitioner · Paramount, CANPI 1982870291
Payments from drug & device makers
Across 108 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$474
- Lilly USA, LLC$414
- Novo Nordisk$266
- Phathom Pharmaceuticals, Inc.$243
- Merck$174
- AstraZeneca$121
- plus $694 from 17 others
What the payments were for
- Food & beverage$2,387100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 20 | $474 |
| Lilly USA, LLC | 19 | $414 |
| Novo Nordisk | 16 | $266 |
| Phathom Pharmaceuticals, Inc. | 6 | $243 |
| Merck | 10 | $174 |
| AstraZeneca | 6 | $121 |
| GSK | 5 | $105 |
| Amgen | 4 | $85 |
| Amarin Pharma, Inc. | 3 | $71 |
| Abbott | 3 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $59 |
| Hologic Sales And Service, LLC | 2 | $47 |
| Phadia US Inc. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 1 | $33 |
| Exact Sciences | 1 | $30 |
| Pfizer | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Gilead | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Cranial Technologies, Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Cipher Pharmaceuticals US LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$123
How this compares
$2,387 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 115 | $166,580 |
| JardianceEmpagliflozin | 97 | $105,292 |
| OzempicSemaglutide | 88 | $103,538 |
| XifaxanRifaximin | 23 | $77,633 |
| FarxigaDapagliflozin Propanediol | 73 | $75,652 |
| ProliaDenosumab | 42 | $66,263 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 97 | $51,855 |
| JanumetSitagliptin Phos/Metformin Hcl | 45 | $47,708 |
| TrulicityDulaglutide | 20 | $24,343 |
| EliquisApixaban | 15 | $21,501 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $14,087 |
| RybelsusSemaglutide | 13 | $13,289 |
| MounjaroTirzepatide | 12 | $12,130 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,186 |
| Diclofenac Sodium | 87 | $7,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $174 | $214,288160 claims |
| Novo NordiskOzempic, Rybelsus | $266 | $116,827101 claims |
| Boehringer IngelheimJardiance | $22 | $105,29297 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $121 | $85,83890 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $15 | $77,63323 claims |
| AmgenProlia | $85 | $66,26342 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $414 | $36,47332 claims |
| PfizerEliquis | $28 | $21,50115 claims |
| GSKBreo Ellipta | $105 | $4,74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Paramount
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.